19215 Rec'd PCT/PTO 1 7 OCT 2006.

TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A SUBMISSION UNDER 35 U.S.C. 371

CUSTOMER NO. 22,852 ATTORNEY'S DOCKET NUMBER: 03715.0152-0

U.S. APPLICATION NO. (If known, see 37 CFR 1.5) 10/566,386

INTERNATIONAL APPLICATION NO. PCT/IB04/02374

INTERNATIONAL FILING DATE
July 5, 2004

PRIORITY DATE CLAIMED July 30, 2003

TITLE OF INVENTION

TRANSGENIC MICE HAVING A HUMAN MAJOR HISTOCOMPATIBILITY COMPLEX (MHC) PHENOTYPE, EXPERIMENTAL USES AND APPLICATIONS

	Com Lex (milo, i letter i e e e e e e e e e e e e e e e e e e
	NT(S) FOR DO/EO/US Claude AURIAULT, Véronique PANCRE, Yu-Chun LONE, Anthony PAJOT, François LEMONNIER
Applicant(	s) herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:
1. 🗆	This is a FIRST submission of items concerning a filing under 35 U.S.C 371.
2. 🖾	This is a SECOND or SUBSEQUENT submission of items concerning a submission under 35 U.S.C. 371.
3.	This is an express request to begin national examination procedures (35 U.S.C. 371(f)). The submission must include items (5), (6), (9) and (21) indicated below.
4.	The US has been elected (Article 31).
5. 🔲	A copy of the International Application as filed (35 U.S.C. 371 (c)(2)).
	a.  is attached hereto (required only if not communicated by the International Bureau).
	b.  has been communicated by the International Bureau.
	c. is not required, as the application was filed with the United States Receiving Office (RO/US).
6. 🗆	An English language translation of the International Application as filed (35 U.S.C. 371(c)(2)).
	a. is attached hereto.
	b. has been previously submitted under 35 U.S.C. 154(d)(4).
7. 🗆	Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371 (c)(3)).
_	a.  are attached hereto (required only if not communicated by the International Bureau).
	b.  have been communicated by the International Bureau.
	c. have not been made; however, the time limit for making such amendments has NOT expired.
	d. have not been made and will not be made.
8.	An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371 (c)(3)).
9. 🖂	An oath or declaration of the inventor(s) (35 U.S.C. 371 (c)(4)).
10.	An English language translation of the annexes of the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371 (c)(5)).
Items 11 to 20 below concern document(s) or information included:	
11. 🗆	Information Disclosure Statement under 37 CFR 1.97 and 1.98
12.	An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.
13.	A preliminary amendment.
14.	An Application Data Sheet under 37 CFR 1.76.
15.	A Substitute specification.
16. 🗆	A power of attorney and/or change of address letter.
17.	A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 35 U.S.C. 1.821-1.825.
18.	A second copy of the published International Application under 35 U.S.C. 154 (d)(4).
19.	A second copy of the English language translation of the international application 35 U.S.C. 154 (d)(4).
20.	Other items or information:
	<ul> <li>a.           Response To Notification Of Missing Requirements Under 35 U.S.C. §371 In The United States Designated/Elected         Office (Do/Eo/Us)</li> </ul>
	b. Copy of Notification of Missing Requirements.
	c. Statement to Support Filing and Submission in Accordance With 37 C.F.R. § 1.821-1.825
1	d